Your browser doesn't support javascript.
loading
RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets.
Carter, Corey A; Oronsky, Bryan T; Caroen, Scott Z; Scicinski, Jan J; Degesys, Aiste; Kim, Michelle M; Oronsky, Arnold L; Lybeck, Harry; Cabrales, Pedro; Oronsky, Neil; Reid, Tony; Roswarski, Joseph; Brzezniak, Christina.
Afiliación
  • Carter CA; Walter Reed National Military Medical Center, Murtha Cancer Center, Bethesda, Md., USA.
  • Oronsky BT; EpicentRx Inc., Mountain View, Calif., USA.
  • Caroen SZ; EpicentRx Inc., Mountain View, Calif., USA.
  • Scicinski JJ; EpicentRx Inc., Mountain View, Calif., USA.
  • Degesys A; Walter Reed National Military Medical Center, Murtha Cancer Center, Bethesda, Md., USA.
  • Kim MM; Department of Radiation Oncology, University of Michigan, Ann Arbor, Mich., USA.
  • Oronsky AL; InterWest Partners, Menlo Park, Calif., USA.
  • Lybeck H; Department of Physiology, University of Helsinki, Helsinki, Finland.
  • Cabrales P; Department of Bioengineering, University of California San Diego, La Jolla, Calif, USA.
  • Oronsky N; CFLS Data, Mountain View, Calif., USA.
  • Reid T; Moores Cancer Center, University of California San Diego, La Jolla, Calif., USA.
  • Roswarski J; Walter Reed National Military Medical Center, Murtha Cancer Center, Bethesda, Md., USA.
  • Brzezniak C; Walter Reed National Military Medical Center, Murtha Cancer Center, Bethesda, Md., USA.
Case Rep Oncol ; 9(1): 171-6, 2016.
Article en En | MEDLINE | ID: mdl-27065849
ABSTRACT
RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903), which reexposes patients to previously effective but refractory platinum doublets after treatment with RRx-001. The purpose of this case study is first to report a partial response to carboplatin and etoposide in a patient with small-cell lung cancer pretreated with RRx-001, indicating episensitization or resensitization by epigenetic mechanisms, and second to discuss the literature related to small-cell lung cancer and episensitization.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Case Rep Oncol Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Case Rep Oncol Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos